Defunct Company
Total Trials
8
As Lead Sponsor
As Collaborator
0
Total Enrollment
515
NCT00539344
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 31, 2007
Completion: Mar 31, 2010
NCT00539383
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
NCT01480583
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Phase: Phase 2
Start: Oct 31, 2011
Completion: Oct 31, 2015
NCT01497665
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)
Start: Nov 30, 2011
Completion: Feb 28, 2013
NCT01967810
ANG1005 in Patients With Recurrent High-Grade Glioma
Start: Oct 31, 2013
Completion: Sep 30, 2017
NCT02048059
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Start: Apr 30, 2014
NCT03613181
ANG1005 in Leptomeningeal Disease From Breast Cancer
Phase: Phase 3
Start: Dec 31, 2023
Completion: Dec 31, 2024